United States Patent 12,594,326: Granule-Based Semaglutide Composition Claims, Scope Boundaries, and US Patent Landscape
Executive summary: US 12,594,326 claims a two-type granule oral pharmaceutical composition in which one granule fraction is SNAC-rich (≥70% w/w SNAC; <10% w/w lubricant) and the other is semaglutide-rich at controlled excipient levels (semaglutide present; ≥15% w/w filler; <40% w/w binder). Dependent claims lock lubricant to magnesium stearate, filler to microcrystalline cellulose, and binder to povidone, with additional “does not comprise” exclusions for semaglutide and SNAC in the respective granule types. The claim set is narrow on (i) the granule architecture (two fractions), (ii) the mass % thresholds for SNAC, lubricant, filler, and binder, and (iii) the assignment of SNAC to only the first granule type and semaglutide only to the second. Practical design-arounds focus on breaking one of these threshold/exclusivity constraints, altering granule composition ratios, changing excipient identity, or eliminating the two-type granule structure.
What patents protect US 12,594,326 granule-based semaglutide SNAC compositions?
Answer: US 12,594,326 is positioned as a formulation composition patent centered on a specific granule split architecture for oral semaglutide exposure, with SNAC confined to a first granule type and semaglutide confined to a second granule type under defined excipient mass % limits.
Claim 1 anchor: two-type granule architecture with mass % limits
Independent claim 1 defines the core protected subject matter:
- A pharmaceutical composition with first type and second type granules.
- First type granules:
- ≥70% w/w SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylic acid)
- <10% w/w lubricant
- Second type granules:
- Semaglutide present
- ≥15% w/w filler
- <40% w/w binder
This claim scope is driven by a structural excipient allocation: SNAC is carried in one granule fraction at very high concentration, while semaglutide sits in a different granule fraction with its own excipient limits.
Dependent claims: excipient identity and “absence” limitations
The dependent claims further tighten the scope.
- Claim 2: lubricant is magnesium stearate.
- Claim 3: filler is microcrystalline cellulose.
- Claim 4: binder is povidone.
- Claim 5: first granules do not comprise semaglutide.
- Claim 6: second granules do not comprise SNAC.
- Claim 7: both exclusivity constraints apply simultaneously.
- Claim 8: combines the excipient identity locks (magnesium stearate, microcrystalline cellulose, povidone).
- Claims 9-11: combine claim 8 with the semaglutide/SNAC absence requirements.
Legal significance of “does not comprise” limitations
For composition claims, the “does not comprise” language typically acts as a negative limitation that can narrow infringement to products where the specified component is absent (or, depending on claim construction, absent in the relevant granule type above a de minimis level). Here, the negative limitations are essential to the claimed granule-type allocation: SNAC must be confined to the first fraction and semaglutide confined to the second.
What is the exact scope of the claims and where are the boundary lines?
Answer: Infringement turns primarily on satisfying every limitation in claim 1 (and then, for narrower claims, satisfying additional identities and exclusions). The boundary lines are the two-type granule structure and the specific mass % ranges.
Claim 1 scope checklist (potential infringement elements)
To fall within claim 1, a US product would need:
- Two distinct granule types in the same pharmaceutical composition.
- First granules contain:
- SNAC at ≥70% w/w; and
- lubricant at <10% w/w.
- Second granules contain:
- semaglutide; and
- filler at ≥15% w/w; and
- binder at <40% w/w.
- The claim does not, in claim 1, require:
- the lubricant to be magnesium stearate
- filler to be microcrystalline cellulose
- binder to be povidone
- the explicit absence of semaglutide from first granules or SNAC from second granules
Those absence limits only appear in claims 5-7 and 9-11.
Boundary lines created by the numeric thresholds
Because the claim uses hard mass percentage thresholds, products sit on either side of discrete infringement boundaries:
- SNAC: ≥70% w/w in first granules is required.
- Moving below 70% is a direct route to avoid claim 1 (unless other claims cover the revised ratios).
- Lubricant: <10% w/w in first granules is required.
- Raising lubricant to 10% or more in first granules can be a design-around.
- Filler: ≥15% w/w in second granules is required.
- Dropping filler below 15% can avoid claim 1.
- Binder: <40% w/w in second granules is required.
- Moving binder to 40% or more can avoid claim 1.
Boundary lines created by granule allocation
Even in claim 1, the two-type granule architecture is required. Dependent claims add allocation constraints:
- Claim 5: first granules lack semaglutide.
- Claim 6: second granules lack SNAC.
- Claim 7: both constraints.
These limits can be used tactically in formulation design:
- If a formulation includes trace semaglutide in the SNAC-rich fraction, claim 5 and claim 7 are harder to satisfy.
- If a formulation includes trace SNAC in the semaglutide-rich fraction, claim 6 and claim 7 are harder to satisfy.
Practical scope implications for process and manufacturing
While the claims are written as composition claims, infringement can be tested by:
- granule characterization (lab assays, fraction separation validation),
- excipient content quantification per granule type,
- and the presence/absence of semaglutide or SNAC in each fraction.
This pushes enforcement toward analytical chemistry and fraction-specific measurement rather than only bulk composition analysis.
Which formulations are likely covered by US 12,594,326?
Answer: Covered formulations are those where semaglutide and SNAC are partitioned into two granule populations with SNAC concentrated to at least 70% w/w in the SNAC granules, while the semaglutide granules include a filler fraction at at least 15% w/w and a binder at below 40% w/w. The narrow dependent layer covers specific excipient identities and strict exclusivity between granule types.
Coverage map by claim layer
| Claim |
Key limitations |
Likely covered formulation characteristics |
| 1 |
Two granule types; SNAC ≥70% w/w in first; lubricant <10% w/w in first; semaglutide in second; filler ≥15% w/w in second; binder <40% w/w in second |
Two-fraction granulation with extreme SNAC enrichment and controlled excipient ratios |
| 2 |
Lubricant = magnesium stearate |
Magnesium stearate used in SNAC granules, while still meeting <10% w/w |
| 3 |
Filler = microcrystalline cellulose |
MCC used as filler in semaglutide granules at ≥15% w/w |
| 4 |
Binder = povidone |
Povidone used as binder in semaglutide granules at <40% w/w |
| 5 |
First granules do not comprise semaglutide |
Semaglutide exclusively confined to second granules (strict partitioning) |
| 6 |
Second granules do not comprise SNAC |
SNAC exclusively confined to first granules |
| 7 |
Both exclusivity constraints |
Strong partitioning architecture |
| 8 |
Combines 2-4 |
magnesium stearate + MCC + povidone with claim 1 structure |
| 9-11 |
Combine claim 8 with absence limits |
Narrowest set with fixed excipient identities and strict absence in respective fractions |
When does US 12,594,326 lose exclusivity, and what drives the end date?
Answer: The user-provided content does not include the patent’s filing date, priority, issuance date, or any term adjustments. Without those, an accurate exclusivity timeline and expiration date cannot be produced.
What generic entry risks exist for granule-partitioned oral semaglutide under this patent?
Answer: The primary generic or follow-on product risk is composition-architecture infringement. A generic product must show that it does not meet claim 1’s two-type granule structure plus the mass % and allocation boundaries, or that any relevant dependent claim limitations are not met.
High-risk vs lower-risk design-around strategies
High-risk (likely closer to infringement):
- Use SNAC in the first granule type at ≥70% w/w.
- Keep lubricant in first granules below 10% w/w.
- Include semaglutide in the second granule type.
- Use filler at ≥15% w/w in second granules.
- Use binder at <40% w/w in second granules.
Lower-risk approaches (conceptual):
- Adjust SNAC concentration in first granules to <70% w/w.
- Increase lubricant in first granules to ≥10% w/w.
- Reduce filler in semaglutide granules to <15% w/w.
- Increase binder in semaglutide granules to ≥40% w/w.
- Disrupt strict partitioning to avoid dependent claim “does not comprise” constraints (for example, ensure semaglutide is present in first granules above a claim-relevant threshold, or ensure SNAC is present in second granules above that threshold), while still recognizing this can also affect other claims not provided.
How strong is the patent estate for oral semaglutide granule compositions like this?
Answer: Based on the provided claims only, US 12,594,326’s strength is tied to how commercially prevalent the claimed granule architecture is among competing oral semaglutide products and how consistently competitors adhere to (or deviate from) these numeric thresholds and granule allocation constraints.
Strength factors in the provided claim set
- Numeric thresholds create clear design-around lines.
- “Two granule types” introduces a discrete formulation structure limitation.
- Dependent claims lock excipient identity and add “absence” limitations, which are enforceable if the opponent’s analytics show compliance.
Weakness factors (relative, based on claim language)
- Numeric thresholds are narrow, which means a competitor can plausibly clear noninfringement by altering formulation ratios.
- “Does not comprise” limitations can turn into evidentiary battles about detection thresholds and what counts as “comprise” in the specific granule fractions.
What is the Orange Book status of US 12,594,326?
Answer: The provided information contains no Orange Book listings, drug product, NDA/BLA number, or listed patents. No Orange Book status can be produced from the supplied dataset.
What patent litigation affects US 12,594,326?
Answer: No litigation dataset, parties, or case captions are provided, so litigation impact cannot be determined.
How does US 12,594,326 compare with typical SNAC-based oral semaglutide patents?
Answer: This patent is best read as a granule-partition and excipient-ratio claim rather than a broad SNAC use claim. Many oral semaglutide patent families include:
- SNAC solid-state forms,
- general compositions containing SNAC and semaglutide,
- methods for preparing or administering,
- and variability around excipient selection.
US 12,594,326 differs by:
- requiring two discrete granule types, and
- requiring very high SNAC concentration in one granule type and strict excipient ratio windows in the other.
What manufacturing/IP barriers do the claim limitations create?
Answer: The claim language drives manufacturing choices and controls analytical verification.
Analytical enforcement targets
Because the claim is fraction-specific, a challenge typically includes:
- separating first granules from second granules,
- quantifying SNAC, lubricant, filler, and binder per fraction,
- and confirming “does not comprise” conditions for semaglutide/SNAC in the specified granule type for dependent claims.
Formulation development implications
To reduce infringement risk, developers are incentivized to:
- avoid the specific mass % targets in each granule type,
- and avoid strict partitioning that matches the dependent claims.
Key Takeaways
- US 12,594,326 protects an oral semaglutide composition built from two granule types with fraction-specific excipient allocation.
- Claim 1 hinges on four numeric gates: SNAC ≥70% w/w and lubricant <10% w/w in the first granules; filler ≥15% w/w and binder <40% w/w in the second granules.
- Dependent claims narrow further with magnesium stearate (lubricant), microcrystalline cellulose (filler), and povidone (binder) plus absence requirements for semaglutide or SNAC in the respective granule types.
- The most direct generic design-arounds are to miss one of the numeric thresholds or to break the granule allocation constraints underpinning dependent “does not comprise” claims.
- Expiration, Orange Book status, and litigation impact cannot be derived from the provided claim text alone.
FAQs
1. What excipients are required for infringement of dependent claims?
Claim 2 requires magnesium stearate as lubricant; claim 3 requires microcrystalline cellulose as filler; claim 4 requires povidone as binder, layered onto the claim 1 granule architecture.
2. Can a product infringe claim 1 if lubricant in the SNAC granules is 10% w/w?
No, claim 1 requires lubricant in first granules to be less than 10% w/w.
3. Does claim 1 require that semaglutide be absent from the SNAC granules?
No. That absence is required only in claim 5 (and in claim 7).
4. Does claim 1 require that SNAC be absent from the semaglutide granules?
No. That absence is required only in claim 6 (and in claim 7).
5. What is the key risk for a generic attempting a two-granule architecture?
If the generic uses two granule types with SNAC at ≥70% w/w in the first fraction and meets the second fraction filler/binder limits (filler ≥15% w/w; binder <40% w/w) while including semaglutide in the second granules, it is at material risk for claim 1 exposure.
References
- Provided claims text for US Drug Patent 12,594,326 (user input).
